Intellia Therapeutics Reports Q1 2026 Loss as Revenue Falls Short of Zacks Estimates

Intellia Therapeutics, Inc. (NASDAQ: NTLA) reported a first-quarter 2026 loss while also missing Zacks’ revenue expectations, according to the latest earnings coverage. The biotechnology company posted an earnings surprise of +11.60%, but its revenue came in below expectations with a -3.12% surprise for the quarter ended March 2026.

Q1 Results Show Mixed Performance

Intellia’s latest quarterly report presented a mixed picture for investors. On one side, the company delivered a smaller-than-expected loss, suggesting better cost control or operational discipline. On the other side, revenue failed to meet Wall Street expectations, which may raise concerns about near-term commercial momentum.

MarketBeat data showed Intellia reported an actual loss of $0.81 per share, compared with the consensus estimate of a $0.92 loss per share. Revenue was listed at about $15.05 million, compared with an expected $13.81 million.

Pipeline Progress Remains the Main Story

Although the financial results drew attention, Intellia’s long-term investment case remains closely tied to its gene-editing pipeline. The company said it presented positive Phase 3 HAELO topline data for lonvo-z, its treatment candidate for hereditary angioedema, and has begun a rolling BLA submission.

The HAELO study showed that a one-time infusion of lonvo-z reduced hereditary angioedema attacks by 87% versus placebo during the six-month evaluation period. Intellia also reported that 62% of treated patients were attack-free and therapy-free.

Regulatory Milestones Could Shape Future Growth

Intellia expects a possible U.S. launch of lonvo-z in the first half of 2027, assuming regulatory approval. The company also recently resumed patient screening in the MAGNITUDE and MAGNITUDE-2 Phase 3 trials for nex-z, which is being studied for ATTR cardiomyopathy and ATTR polyneuropathy.

This is important because Intellia’s current revenue base is still limited, and the company’s future depends heavily on successful clinical development, regulatory approval, and eventual commercialization of its lead programs.

Cash Position Supports Operations

Intellia stated that, including proceeds from its April public offering, its existing cash resources are expected to fund operations at least into 2028. This gives the company more time to advance its late-stage programs without immediate financing pressure.

Investor Takeaway

Intellia’s Q1 2026 earnings report shows a company still operating at a loss, but making meaningful progress in clinical development. The revenue miss may disappoint some investors, yet the smaller-than-expected loss and strong lonvo-z data could keep attention focused on the company’s long-term potential.

For investors, the key factors to watch are the progress of the rolling BLA submission for lonvo-z, updates from the nex-z trials, regulatory feedback, and whether Intellia can move from clinical success to commercial execution.

Overall, Intellia Therapeutics remains a high-risk, high-potential biotech stock, with its future value closely linked to the success of its CRISPR-based therapies.

#IntelliaTherapeutics #NTLA #BiotechStocks #GeneEditing #SlimScan #GrowthStocks #CANSLIM